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Chondrosarcomas are malignant cartilaginous tumors arising centrally in bone (central chondrosarcoma), or secondarily within
the cartilaginous cap of a hereditary or sporadic exostosis (peripheral chondrosarcoma). Loss of heterozygosity (LOH) was
studied by microsatellite analysis at the loci harboring the EXT genes (implicated in hereditary multiple exostoses), the EXT-like
genes, and at 9p21, 13q14, 17p13, and chromosome 10. Nineteen of 20 peripheral chondrosarcomas showed LOH at all loci
tested, while only 3 of 12 central chondrosarcomas exhibited LOH, restricted to 9p21, 10, 13q14, and 17p13. LOH at 9p21 did
not appear to involve the CDKN2A gene, as assessed by SSCP analysis. DNA flow cytometry demonstrated a wide variation in
the ploidy status in peripheral chondrosarcomas (DNA indexes, 0.56–2.01), whereas central chondrosarcomas were
predominantly peridiploid. Near-haploidy found in peripheral chondrosarcomas could explain part of the high LOH percent-
ages. Ki-67 immunohistochemistry suggested a higher proliferation rate in peripheral chondrosarcomas. Our results indicate
that peripheral chondrosarcomas, arising secondarily to an exostosis, may obtain genetic alterations during malignant
transformation, with subsequent genetic instability as demonstrated by a high percentage of LOH and a wide variation in ploidy
status. In contrast, peridiploidy and a low percentage of LOH in central tumors suggest that a different oncogenic molecular
mechanism may be operative. Genes Chromosomes Cancer 26:237–246, 1999. r 1999 Wiley-Liss, Inc.
INTRODUCTION
Chondrosarcomas are relatively rare, malignant
cartilage-forming tumors, generally presenting be-
tween 35 and 60 years of age. It is the second most
frequent primary malignant bone tumor after osteo-
sarcoma. The majority of chondrosarcomas (75%)
are located centrally within the medullar cavity
(central chondrosarcoma), whereas 15% develop
from the surface of bone (peripheral chondrosar-
coma) (Mulder et al., 1993; Springfield et al., 1996).
The majority of central chondrosarcomas are consid-
ered to arise de novo, while a small number arise
secondarily to an enchondroma, often in patients
demonstrating nonhereditary multiple enchondro-
mas (Ollier’s disease or Maffucci’s syndrome) (Mul-
der et al., 1993). In contrast, peripheral chondrosar-
comas usually arise within the cartilage cap of a
long-standing osteochondroma (exostosis). Malig-
nant transformation is low in solitary osteochondro-
mas (,1%), but is estimated to occur in 1%–5% of
cases of hereditary multiple exostoses (HME), a
familial disorder with an autosomal dominant mode
of inheritance (Schmale et al., 1994; Wicklund et
al., 1995). There are no apparent cytonuclear differ-
ences between central and peripheral chondrosarco-
mas and both subtypes are histologically classified
into three grades, correlating with prognosis, using
the criteria of Evans et al. (1977).
HME is a genetically heterogeneous disorder for
which at present two genes, EXT1 and EXT2,
located respectively on 8q24 and 11p11–p12, have
been isolated (Ahn et al., 1995; Stickens et al., 1996;
Wuyts et al., 1996). Additionally, linkage to chromo-
some 19p has been found, suggesting the existence
of an EXT3 gene (Le Merrer et al., 1994). Recently,
the EXT1 and EXT2 gene products were shown to
be glycosyltransferases required for the biosynthe-
sis of heparan sulfate (Lind et al., 1998; McCormick
et al., 1998) and an EXT1 homologue in Drosophila
(tout-velu) was demonstrated to be required for
diffusion of the morphogen Hedgehog (Bellaiche et
al., 1998). Recently, three new genes, EXTL1,
EXTL2, and EXTL3, have been isolated based on
their homology to the EXT1 and EXT2 genes (Wise
et al., 1997; Wuyts et al., 1997; Van Hul et al., 1998)
and, as for the EXT genes, a tumor suppressor
function was suggested (Hecht et al., 1995; Raskind
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et al., 1995; Wuyts et al., 1997; Van Hul et al., 1998).
Loss of heterozygosity (LOH) at the EXT loci on
chromosomes 8 and 11 has been described in
chondrosarcoma (Hecht et al., 1995; Raskind et al.,
1995); LOH at loci linked to the EXTL genes has
not as yet been reported.
To investigate whether different genetic alter-
ations are involved in the oncogenesis of peripheral
and central chondrosarcomas, we studied LOH at
the EXT and EXTL loci, as well as at other loci of
(putative) tumor suppressor genes reported to be
involved in incidental cases of chondrosarcoma,
e.g., RB1 (13q14), TP53 (17p13), CDKN2A/CDKN2B
(9p21), and chromosome 10 (Jagasia et al., 1996;
Raskind et al., 1996; Yamaguchi et al., 1996). The
majority of peripheral chondrosarcomas showed
LOH in a high percentage at all different loci
analyzed, whereas only 3 of 12 central tumors
showed LOH restricted to 9p21, 10, 13q14, and
17p13. To investigate whether this difference in
LOH incidence might be explained by a difference
in ploidy status, we performed DNA flow cytome-
try. CDKN2A mutation analysis and TP53 immuno-
histochemistry were done to estimate the specific-
ity of the LOH found. Additionally, we performed
Ki-67 immunohistochemistry to determine a poten-
tial difference in proliferative activity.
MATERIALS AND METHODS
Patient Data
In total, 58 tumors from 49 patients (peripheral
chondrosarcoma [n 5 26], central chondrosarcoma
[n 5 21], and metastases of 2 additional patients
with central chondrosarcoma) were retrieved from
the files of the Leiden University Medical Center, a
tertiary bone tumor referral center. Dedifferenti-
ated, mesenchymal, juxtacortical, and clear-cell
chondrosarcomas were excluded, because of the
specific clinicopathological features of these rare
subtypes. Patient data were obtained by review of
pathology specimens and reports, clinical charts,
and radiographs. Central and peripheral chondrosar-
coma were separated based on accepted clinico-
pathological and radiological criteria (Huvos, 1991).
For peripheral chondrosarcoma, a preexisting osteo-
chondroma or an identifiable stalk was documented
either radiographically at gross pathology or speci-
men X-ray in 25 of 26 cases. Multiplicity of osteo-
chondromas, which could be retrieved for 22 of 26
cases, was considered the criterion for HME since
an unequivocal family history was not always avail-
able. Seven of 22 peripheral chondrosarcomas were
HME-related, whereas 15 cases developed within a
sporadic osteochondroma. Histological grading was
performed according to Evans et al. (1977). Four
tumors were diagnosed as borderline chondrosar-
coma since they showed histological features that
were not sufficient to diagnose grade I chondrosar-
coma while their roentgenograms showed features
of an aggressive neoplasm (Unni, 1996). Patient
data of all 47 patients with primary tumors are
presented in Table 1.
Loss of Heterozygosity Study and CDKN2A
SSCP Analysis
Sample preparation
Of the 47 patients, fresh-frozen tumor tissue and
matched normal DNA was available for 21 periph-
eral chondrosarcomas of 20 patients (17 primary and
4 recurrent tumors) and 14 central chondrosarcomas
(11 primary and 3 recurrent tumors) of 12 patients.
Additionally, metastases of three patients with cen-
tral chondrosarcoma were included. Five of the
patients for whom fresh-frozen tissue of peripheral
chondrosarcoma was available for molecular analy-
sis were suffering from HME. Tumor cell percent-
ages had to be at least 60% to be included, as
determined using hematoxylin and eosin-stained
cryostat-sections. Of five peripheral chondrosarco-
mas, additional flow cytometric cell sorting was
used to enrich the tumor cell fraction. Normal DNA
was prepared from peripheral blood, drawn from
TABLE 1. Clinical and Tumor-Related Data for All Patients
Peripheral (n 5 26) Central (n 5 21)
Male vs. female 13 vs. 13 6 vs. 15
Median age at diag-
nosis (years) 39.8 (16–68) 40.1 (14–73)
Histology
Borderline 1 3
Grade I 10 9
Grade II 11 7
Grade III 4 2
Hereditary multiple
exostoses 7/22a 0/21




(months) 32 (10–159, n522) 32 (1–190, n521)
Disease-free survivalc
(months) 53 33
aPatients with inconclusive data are omitted.
bNumber of peripheral chondrosarcomas in which a preexisting osteo-
chondroma was documented and number of central chondrosarcomas
that were proven to be secondary to an enchondroma.
cComputed using Kaplan Meier survival curves; interval until 25% of the
patients developed local recurrence or metastases; no difference in
disease-free survival was found (log-rank test, P 5 0.70).
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patients after informed consent or from fresh-
frozen muscle tissue obtained from resected speci-
mens.
DNA-isolation
DNA isolation from fresh-frozen tissue was per-
formed using proteinase-K treatment and phenol-
chloroform extraction as described (Devilee et al.,
1989) with some modifications. Before protein-
ase-K digestion, cartilaginous tumor tissue was
preincubated with hyaluronidase in a 3 M NaAc
buffer, pH 5.6, for 2 hr at 37°C. Then the pH was
adjusted by adding 1/8 volume of 2 M NaOH. DNA
from freshly collected blood samples was isolated
using a salting-out procedure (Miller and Polesky,
1988).
Loss of heterozygosity study
Analysis of microsatellite markers was performed
by PCR on 100 ng DNA as described (Weber and
May, 1989) using [a32P]dCTP in a total volume of
12 µl. Thermal cycling was performed in a program-
mable heat block (MJ research, Watertown, MA)
consisting of 27 cycles with an annealing tempera-
ture of 55°C. For PCR on flow-sorted nuclei, 33
cycles were applied. Primers linked to the EXT and
EXT-like regions were chosen based on published
data (Cook et al., 1993; Le Merrer et al., 1994;
Hecht et al., 1995; Raskind et al., 1995; Stickens et
al., 1996; Wise et al., 1997; Wuyts et al., 1997). Apart
from D11S903, which is an intragenic marker in
EXT2, all markers are in the near vicinity of the
respective genes. In addition, primers were chosen
in the TP53 (Yamaguchi et al., 1996) and RB1
(Yamaguchi et al., 1996) region, at 9p21 (Jagasia et
al., 1996), 10p15, and 10q11 (Raskind et al., 1996)
(Table 2). D13S153 and D9S171 are within 1 cM
from the RB1 and CDKN2A genes, respectively.
Additionally, random LOH was investigated to
estimate background LOH using a marker at chro-
mosome arm 4p, since this region was never de-
scribed to be involved in chondrosarcoma. Polymor-
phic markers are described in the Genome Database
(http://gdbwww.gdb.org). After electrophoresis on a
6.5% polyacrylamide gel containing 7 M urea, gels
were dried and exposed to X-ray films. Signal
intensities were measured by Phosphor Imaging
(Molecular Dynamics, Sunyvale, CA). LOH was
scored when the quotient of the ratios of both
alleles of normal and tumor was larger than or equal
to 1.7 (Gruis et al., 1993). Ratios between 1.3 and
1.7 were regarded inconclusive and excluded from
the analysis (Devilee et al., 1991). LOH had to be
reproducible to be included.
CDKN2A SSCP analysis
PCR was performed as described (Gruis et al.,
1995) on DNA from 11 tumors showing LOH at
9p21 (7 peripheral, 3 central, and 1 metastatic
tumor). For exon 2, three overlapping fragments
were amplified (Gruis et al., 1995), whereas exons 1
and 3 were covered with single PCR products
(Hussussian et al., 1994). Samples were run on a 6%
glycerol/6% polyacrylamide gel for 6 hr. Gels were
dried and exposed to X-ray films.
Flow Cytometry
Of the 47 patients, fresh-frozen tumor tissue for
DNA ploidy analysis was available for 21 peripheral
and 17 central chondrosarcomas and 4 patients with
metastases. Single cell suspensions from fresh-
frozen tissue for single parameter nuclear DNA
flow cytometry were prepared by the method of
Vindelov et al. (1983a). Cryostat sections were used
to determine tumor percentages. A minimum of
10,000 cells per sample was measured on a FACS-
Calibur flow cytometer (Becton Dickinson, Moun-
tain View, CA). Trout red blood cells served as an
internal standard for determination of the G1 cell
DNA content (Vindelov et al., 1983b). ModFitLT
V2.0 software was used for data acquisition. DNA
histograms were evaluated according to accepted
criteria (Hiddemann et al., 1984). Single cell suspen-
sions from five aneuploid tumor samples (hypodip-
loid [n 5 3] and hyperdiploid [n 5 2]) were sorted
on a FACS Vantage cell sorter (Becton Dickinson)
and DNA was isolated as described (Abeln et al.,
1994).
Immunohistochemical Study
Formalin-fixed, paraffin-embedded material was
available for 44 tumors of 38 patients: 24 peripheral
and 17 central chondrosarcomas and 3 metastases.
Monoclonal antibodies directed to Ki-67, clone
MIB1 (Immunotech SA, Marseilles, France), and
p53, clone DO-7 (DAKO, Glostrup, Denmark),
were used. Immunohistochemical reactions were
performed according to standard laboratory meth-
ods (Bovée et al., 1998). Ki-67–positive nuclei were
counted per 200 tumor cells, in areas containing the
largest number of positive cells. Hematopoietic
cells in bone marrow or skin served as an internal
control. Of the p53 staining, both staining intensity
(1 5 weak, 2 5 moderate, and 3 5 strong intensity)
and the percentage of positive cells (1 5 0%–24%,
2 5 25%–49%, 3 5 50%–74%, and 4 5 75%–100%
positive tumor cells) were evaluated by two observ-
ers independently and a score $ 4 was considered
positive.
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Statistical Analysis
Fisher’s exact test was used to investigate a
difference between peripheral and central tumors
in p53 immunostaining. The Mann-Whitney test
was used to analyze Ki-67 immunoreactivity and to
compare the percentage of LOH in HME-related
tumors compared to sporadic tumors. To investigate
a correlation with histological grade, two groups
were discerned because of the otherwise too small
numbers. Low-grade tumors included borderline
and grade I chondrosarcomas, whereas high-grade
included grade II and grade III tumors. Association
between localization in bone and disease-free sur-
vival was studied using Kaplan Meier survival
curves and the log-rank test.
RESULTS
Loss of Heterozygosity Study and CDKN2A
SSCP Analysis
The partial allelotyping revealed a clear differ-
ence in the LOH pattern and incidence. For
patients with specimens both from the primary
tumor and the recurrence or metastatic tumor,
LOH patterns were concordant for all markers
tested. Nineteen of 20 patients with peripheral
tumors (95%) showed LOH with all 12 loci tested
involved. TP53 (80%) and RB1 (71%) were most
frequently affected (Figs. 1 and 2). Remarkably, the
locus at 4p also demonstrated LOH in 38% of
peripheral tumors. In contrast, only 3 of 12 central
TABLE 2. Microsatellite Markers With Chromosomal Localization and Percentage of Heterozygositya
Marker










EXT1 D8S85 8q23.3 0.74 6/13 0/10 0/2
D8S547 8q24.11 0.66 3/11 0/8 0/2
D8S522 8q24.12–13 0.71 10/13 0/8 0/2
D8S198 8q24.13 0.83 7/18 0/10 0/3
EXT2 D11S905 11p12–13 0.74 7/14 0/9 1/3
D11S903b 11p13–q13 0.74 6/15 0/9 0/2
D11S554 11p11.2–12 0.91 11/17 0/12 1/3
EXT3 D19S216 19pter–qter 0.75 3/15 0/9 0/2
D19S413 19pter–qter 0.76 4/17 0/6 0/2
D19S221 19p13.2 0.86 2/17 0/11 0/3
EXTL1 D1S436 1p36 0.75 4/10 0/9 0/2
D1S470 1p36 0.76 4/12 0/10 0/3
EXTL2 D1S206 1p11–12 0.82 6/13 0/10 0/2
D1S248 1p11–12 0.82 5/13 0/10 0/1
EXTL3 D8S1130 8p12–22 0.93 8/16 0/11 0/3
GATA119C06 8p12–21 8/14 0/6 0/2
D8S283 8p12–21 0.78 4/10 0/8 0/3
D8S1820 8p 0.73 4/11 0/6 0/3
4p D4S174 4p14–21.1 0.92 6/16 0/10 0/2
CDKN2A/CDKN2B D9S43 9p21 0.83 5/15 3/12 2/3
D9S171 9p21 0.80 5/13 3/7 1/2
10p15 D10S89 10pter–p11.2 0.80 5/13 1/7 0/1
D10S559 10p 0.32 3/6 0/2 0/1
D10S1435 10p 0.69 2/9 0/5 0/2
10q11 D10S604 10pter–qter 0.66 1/9 0/4 0/0
D10S538 10pter–qter 0.73 2/12 0/5 0/1
D10S109 10q11.2–qter 0.71 5/16 1/9 0/3
D10S110 10q11.2–qter 0.58 5/12 1/9 0/2
RB1 D13S153 13q14.1–14.3 0.82 10/13 2/11 2/3
D13S155 13q14.3–21.2 0.83 6/12 2/12 1/2
TP53 TP53b 17p13.1 0.69 12/15 0/10 0/3
D17S513 17p13.3 0.89 8/12 1/8 0/3
aFor three patients with specimens both from the primary tumor and the recurrence, LOH patterns were concordant for all markers tested and
therefore only one tumor of each patient is included here. Frequencies of LOH are given as number of tumors showing LOH/number of informative
cases. Percentage of heterozygosity is given according to CEPH data.
bIntragenic marker. More detailed information about the localization with respect to the EXT and EXT-like genes can be found in Stickens et al. (1996),
Cook et al. (1993), Wise et al. (1997), Le Merrer et al. (1994), Hecht et al. (1995), Raskind et al. (1995), and Wuyts et al. (1997).
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chondrosarcomas (25%) showed LOH, restricted to
9p21, 10, 13q14, and 17p13 (Table 2). 9p21 was
involved in all three cases. CDKN2A SSCP analysis
did not reveal any aberrant bands in seven periph-
eral, three central, or one metastatic tumor with
LOH at 9p21.
LOH on chromosome 8 was restricted to the
short arm in three tumors, while four tumors
showed LOH exclusively on the long arm. LOH
restricted to 8p may be directed at inactivation of
the EXTL3 locus. LOH at 8q24 included D8S522 in
all cases. On chromosome 11, D11S554 was in-
volved in LOH in all tumors except one. Interest-
ingly, two tumors showed LOH of D11S554 only.
On 19p both D19S216 and D19S413 were involved
in all four cases showing LOH. The extent of
involvement of adjacent markers varied. LOH on
chromosome 10 involved the whole chromosome in
six cases while two tumors displayed LOH re-
stricted to the short and the long arm, respectively.
DNA Flow Cytometry
DNA ploidy analysis, performed to investigate
whether extensive aneuploidization might explain
the difference in LOH incidence between central
and peripheral tumors, also revealed a clear differ-
ence. Central chondrosarcomas generally showed
peridiploidy except for one grade III tumor (DNA
index, 1.75), while peripheral chondrosarcomas
showed a much wider distribution of DNA indexes,
ranging from 0.56 to 2.01 (Fig. 3). Examples are
shown in Figure 4.
Six peripheral (29%) and one central (6%) tumor
displayed hypodiploid DNA contents (DNA in-
dexes, 0.56–0.93). Hyperdiploidy was demon-
strated in 11 (52%) peripheral and 11 (65%) central
chondrosarcomas (DNA indexes, 1.12–2.01). Five
tumors had more than one aneuploid tumor popula-
tion, among which was one peripheral chondrosar-
coma demonstrating both a hypodiploid (0.76) and
a hyperdiploid (1.56) clone (Fig. 4D). Of four
metastases, three were hyperdiploid and one hypo-
diploid.
The relation between ploidy and the percentage
of LOH per tumor is shown in Figure 5. Interest-
ingly, three hypodiploid tumors were near-haploid
(DNA index, 0.56, 0.70, and 0.76), of which two
were HME-related. Studying LOH, relatively low
Figure 1. Autoradiograms of six tumors displaying LOH. Microsatel-
lite markers are indicated above each panel and allelic imbalance ratios
are indicated below. N: normal tissue; T: total tumor tissue; hypo:
hypodiploid; di: diploid; hyper: hyperdiploid. A: Three peripheral
chondrosarcomas demonstrating LOH at the EXT loci and one central
chondrosarcoma with LOH at 9p21. B: LOH analysis on flow sorted
nuclei: peripheral chondrosarcoma, of which the DNA histogram is
displayed in Figure 4D, showing LOH on chromosome 11 in both the
hypodiploid and hyperdiploid tumor population. On the right LOH at
1p11–12 in hyperdiploid tumor displayed in Figure 4C.
Figure 2. Percentages of LOH for the different loci are depicted for
central and peripheral chondrosarcoma. Peripheral chondrosarcoma is
subdivided into two groups: the upper part of the bar is formed by five
tumors showing either near-haploidy or polyploidization of near-haploid
tumor clones. The lower part of the bar consists of all other peripheral
chondrosarcomas (n 5 14). Percentages were calculated as number of
tumors showing LOH for at least one of the markers divided by the total
number of informative cases.
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allelic imbalance ratios (ranging from 1.5 to 2.5)
were found using total tumor DNA, despite high
tumor percentages. Therefore, enrichment by flow
sorting was utilized to confirm LOH (Fig. 1B).
Diploid and peridiploid tumors showed a relatively
low LOH incidence (0%–50%) except for two grade
III peripheral tumors (DNA index, 1.22 and 1.32)
showing LOH at 92% and 100% of the loci with
remarkably high allelic imbalance factors (mean,
5.04 and 3.2), despite tumor percentages estimated
at 60%. Although not statistically significant, the
total percentage of LOH seemed higher in HME-
related tumors compared to sporadic tumors (71%
vs. 48%, P 5 0.095), which is probably explained by
the fact that two of three near-haploid and one of
the two grade III peripheral tumors with a high
percentage of LOH were HME-related. No correla-
tion between DNA ploidy and histological grade
was seen.
Immunohistochemistry
Although there was a marked difference in LOH
at 17p13 between peripheral and central tumors
(80% vs. 10%), only a small difference in p53
overexpression was seen (46% vs. 25%, P 5 0.32)
(Table 3). High-grade tumors were more frequently
p53-positive than low-grade tumors. Two out of
three metastases showed p53 immunoreactivity. One
case could not be evaluated due to loss of attachment
of tissue sections during microwave procedures.
The Ki-67 index was significantly higher in
peripheral than in central chondrosarcomas (19.63
vs. 7.74, P 5 0.005) (Table 3). After stratification for
low-grade and high-grade tumors, the difference in
proliferative activity was only substantiated in high-
grade chondrosarcomas (25.81 vs. 12.75, P 5 0.031).
In general, high-grade tumors had a statistically
significant higher Ki-67 index than low-grade tu-
mors. The mean Ki-67 index of three metastases
was 19.9%. Of all hypodiploid tumors, the mean
Ki-67 index was 12.4% (range, 2%–25.5%), whereas
the mean Ki-67 index of diploid tumors was 6.77%
(range, 0%–21.5%) and of hyperdiploid tumors
17.1% (range, 0.5%–37.3%). Seven Ki-67–immuno-
stained cases could not be evaluated due to loss of
attachment or due to absence of staining of an
internal positive control. In the latter, prolonged
decalcification may have altered the configuration
of the antigen.
DISCUSSION
A clear difference in the LOH pattern, LOH
incidence, DNA ploidy status, and proliferative
index between central and peripheral chondrosar-
coma was demonstrated in the present study. In
peripheral tumors, displaying a wide variation in
ploidy and a higher proliferation rate, all 12 loci
studied were variously involved in a total of 95% of
the tumors with a high background LOH (38% at
4p). In contrast, tumors developing centrally in
bone displayed peridiploidy and LOH was re-
stricted to 9p21, chromosome 10, 13q14, and 17p13
in 25% of tumors.
So far, in all molecular genetic studies reported in
the literature, no distinction between chondrosar-
coma subtypes has been made. Comparing our data
to those reported in the literature is therefore
difficult, particularly since our results show that
LOH in peripheral chondrosarcoma should be inter-
preted with caution because of the high back-
ground. Nevertheless, the fact that LOH at the
EXT1, EXT2, and EXTL loci seems to rise above
the background LOH and that these loci do not
show LOH in central chondrosarcomas may suggest
that the EXT and EXT-like loci are involved in the
development of peripheral chondrosarcoma only.
The relatively low percentage of LOH using mark-
ers that were linked to a putative EXT3 gene at 19p
(Le Merrer et al., 1994) seems consistent with 19p
microsatellite analysis reported in the literature
(Hecht et al., 1995; Raskind et al., 1995), question-
ing either the localization or the putative tumor
Figure 3. Frequency distribution of DNA indexes in central and
peripheral chondrosarcoma. If two different aneuploid peaks were
found, they are shown separately. Central chondrosarcomas tend to
have peridiploid DNA contents, whereas the DNA content in peripheral
chondrosarcoma varies widely.
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suppressor mechanism of an EXT3 gene at 19p.
LOH in peripheral chondrosarcomas most fre-
quently involved the TP53 (80%) and RB1 (71%)
loci. In the literature, LOH at 13q14 (RB1) was
described in 36% of chondrosarcomas in general
(Yamaguchi et al., 1996), while we detected LOH at
13q14 in 12 out of 17 (71%) peripheral and 2 out of
12 (17%) central tumors.
Using DNA flow cytometry we demonstrated
that central tumors were mostly peridiploid while
peripheral chondrosarcomas had more variable DNA
indexes. Moreover, hypodiploidy, which is uncom-
mon for human solid tumors, was detected in 29%
of peripheral chondrosarcomas. Three flow cytomet-
ric studies have previously shown hypodiploidy in 3
out of 16 (19%) (Xiang et al., 1987), 4 out of 13
(31%) (Mandahl et al., 1993), and 3 out of 37 (8%)
(Heliö et al., 1995) chondrosarcomas. Of 33 chondro-
sarcomas documented cytogenetically, seven (21%)
demonstrated clones with less than 46 chromo-
somes (Sandberg and Bridge, 1994). Three hypodip-
loid cases in our series demonstrated near-haploidy.
Apart from hematological disorders, near-haploidy
has only been described cytogenetically for a small
number of solid tumors. In all cases described, at
least one homolog of each autosome pair is always
present (Atkin and Baker, 1981; Sreekantaiah et al.,
1991; Dal Cin et al., 1998). The presence of
near-haploidy in a subset of peripheral chondrosar-
coma probably explains the high LOH incidence
compared to central chondrosarcoma.
Moreover, p53 immunohistochemistry and
CDKN2A mutation analysis was performed to esti-
mate the specificity of the LOH found. Although a
marked difference in LOH at 17p13 between
peripheral and central tumors (80% vs. 10%) was
found, only a small difference in p53 overexpres-
sion was seen, supporting that at least part of the
LOH in peripheral chondrosarcomas is due to
random chromosome loss. We detected LOH at
9p21 in three central and seven peripheral chondro-
sarcomas. LOH at 9p21 is an uncommon event in
Figure 4. Flow cytometric DNA histograms from nuclear suspen-
sions of peripheral chondrosarcomas. DNA indexes are indicated. TR:
trout red blood cells serving as internal standard. A: Hypodiploidy;
near-haploidy. B: Diploid DNA content. C: Hyperdiploidy. D: Tumor
demonstrating two aneuploid clones of 0.76 and 1.56, respectively. The
trout erythrocytes peak overlaps with the hypodiploid peak and is
therefore not shown. Examples of LOH after flow sorting of the tumors
in panels C and D are shown in Figure 1B.
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mesenchymal tumors and CDKN2A mutations were
absent in osteosarcomas and malignant fibrous
histiocytomas (Liu et al., 1995; Taubert et al., 1998).
We did not detect any band shifts by SSCP analysis
of the CDKN2A gene. Thus, either we missed a
mutation because of the 70%–90% sensitivity of
SSCP analysis, or, more likely, CDKN2A is not the
target gene for LOH in central chondrosarcoma.
LOH at 9p21 in peripheral chondrosarcoma might
also be due to random chromosome loss.
Most of the near-haploid cases documented cyto-
genetically showed polyploidization of the near-
haploid stem line (Atkin and Baker, 1981; Sreekan-
taiah et al., 1991; Dal Cin et al., 1998). We could still
identify the near-haploid fraction (0.76) as well as
the polyploid fraction (1.56) in one tumor (Fig. 4D).
Three peripheral chondrosarcomas demonstrating a
near-haploid tumor population were histologically
grade I (n 5 1) and grade II (n 5 2), and follow-up
(22 and 109 months for two patients) revealed
complete remission. This is consistent with the
favorable prognosis suggested for solid tumors with
very low chromosome numbers (Atkin and Baker,
1981, 1988). The extremely high percentage of
LOH with high allelic imbalance factors in two
tumors with DNA indexes of 1.22 and 1.32 may
probably be explained by polyploidization of near-
haploid clones with DNA indexes of 0.61 and 0.66,
respectively. Both were aggressive grade III chon-
drosarcomas with recurrence at 6 and 27 months.
This might suggest that near-haploidy is associated
with a good prognosis, whereas polyploidization
Figure 5. Scatter diagram of DNA index versus percentage LOH,
calculated per tumor as the percentage of loci showing LOH. Each
tumor is represented by a gray (peripheral) or black (central) circle
(low-grade) or square (high-grade). Central chondrosarcomas demon-
strated a low percentage of LOH and peridiploidy, whereas peripheral
tumors demonstrated a much higher percentage of LOH, especially in
hypodiploid tumors. Asterisk indicates two aneuploid peaks of tumor
displayed in Figure 4D. Of other tumors showing more than one
aneuploid peak, only the most representative population is displayed
since no flow sorting was performed.
TABLE 3. Results of TP53 and Ki-67 Immunohistochemistrya
Peripheral Central Total P
p53-positivity
Low gradeb 1/10 1/12 2/22 1.000
High grade 10/14 3/4 13/18 1.000
Total 11/24 4/16 15/40 0.318
P 0.005c 0.027c 0.000*
Ki-67 index
Low grade 14.07 (10) 6.49 (12) 9.93 (22) 0.142
High grade 25.81 (9) 12.75 (3) 22.54 (12) 0.031c
Total 19.63 (19) 7.74 (15) 14.38 (34) 0.005c
P 0.231 0.326 0.035c
aFor TP53 the number of positive tumors is given per total number of
evaluable tumor samples. For Ki-67 the mean Ki-67 index is given, with
the number of tumors analyzed in brackets.
bLow-grade tumors comprise borderline and grade I chondrosarcomas,
whereas high-grade tumors comprise grade II and III tumors.
cStatistically significant.
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and total overgrowth of the near-haploid clone
increases the aggressiveness of the tumor.
Technical problems encountered in the LOH
study were due to difficulties in estimating contami-
nation with nonneoplastic cells. The often poor
quality of cryostat sections due to the presence of
bony material and the low cellularity of cartilagi-
nous tissue compared to highly cellular contaminat-
ing bone marrow easily leads to overestimation of
tumor percentage. Formalin-fixed, paraffin-embed-
ded bone tumor tissue is not suitable for DNA
extraction and reliable PCR because of DNA degra-
dation by decalcification procedures. The 1:0 allelic
ratio of monosomy, which we showed to be the
underlying event of LOH in a subset of peripheral
chondrosarcomas, is obviously more sensitive to
contamination from normal cells than a 2:0 ratio
(mitotic recombination or polyploidization of near-
haploid clones) (Gruis et al., 1993). This was shown
by the relatively low allelic imbalance ratios using
total tumor DNA of the near-haploid tumors, which
were consequently enriched by flow sorting. We
cannot completely rule out that some of the allelic
imbalance ratios between 1.3 and 1.7, which were
not included in the analysis, are due to monosomy
with contamination by normal nontumor derived
DNA.
Ki-67 immunohistochemistry was performed to
investigate a potential difference in proliferative
activity between central and peripheral tumors. We
demonstrate that the proliferation rate is higher in
peripheral chondrosarcoma, which is not found in
other studies (Scotlandi et al., 1995; Nawa et al.,
1996) in which no correction for histological grade
was made. A correction is required since prolifera-
tion rate was associated with increasing histological
grade, as was also reported previously (Scotlandi et
al., 1995; Nawa et al., 1996).
In conclusion, we demonstrate that central and
peripheral chondrosarcomas, which share a similar
light-microscopic and cytonuclear appearance, may
arise by different genetic mechanisms. We propose
a model in which peripheral chondrosarcomas,
generally arising within benign sporadic or heredi-
tary osteochondromas, obtain genetic alterations
during malignant transformation, which may in-
volve the EXT genes, TP53 and RB1. These
alterations may cause defects in mitotic check-
points leading to chromosomal instability, which in
turn may cause aneuploidy (Cahill et al., 1998). We
demonstrate a high percentage of LOH, ploidy
ranging from half to twice the normal DNA con-
tent, and a higher proliferation rate in peripheral
chondrosarcoma. Near-haploidy was not previously
described in osteochondromas nor identified by
cytogenetic analysis (Mertens et al., 1994; Bridge et
al., 1998) and can therefore be considered a progres-
sion marker toward a malignant phenotype. In
contrast, in central chondrosarcoma a low percent-
age of LOH and peridiploidy was found. LOH was
most frequent at 9p21. Other genetic events, like
microsatellite instability, could not be demon-
strated and therefore an as yet unknown, perhaps
single genetic alteration sufficient for oncogenesis
remains to be identified in central chondrosarcoma.
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